This LEAD Award proposal is an integrated project designed to test the hypothesis that late onset Alzheimer's Disease (LOAD) is genetic and to identify the genetic loci for LOAD and early onset familial AD (EOAD). EOAD is linked to anonymous DNA probes on chromosome 21 so that experiments designed to identify and describe the genetic locus will focus on chromosome 21 specific expression differences in EOAD. A clinical genetic ascertainment and family development program for EOAD and LOAD is described. Sib-pair screening and standard likelihood analyses are presented. Subtraction hybridization (using tissue available from the Duke Alzheimer's Disease Research Center Rapid Autopsy Protocol), candidate gene analyses, chromosome mapping techniques, and other molecular genetic strategies to define the chromosome 21 gene locus for EOAD and a putative gene(s) for LOAD are described. The LEAD proposal is organized into six integrated projects including two junior investigator projects and three pilot projects. The LEAD project (ROSES) includes the family development and screening for linkage to LOAD, as well as experiments designed to test chromosome 21 specific gene expression differences in EOAD and control brain regions. Junior investigator Project 1 (CLARK) describes the detailed plan for continued and expanded clinical ascertainment and development of LOAD and EOAD families. Junior investigator Project 2 (ALBERTS) describes brain region specific subtraction hybridization experiments in LOAD. Pilot Project 1 (BREITNER) develops twin studies that can provide additional families of interest for gene mapping. Pilot Project 2 (DAWSON) develops the sib-pair methodology to be applied to late onset families in which the DNA of several of the affected individuals are unavailable but whose genotype can be inferred from family data. Pilot Project 3 (BARTLETT) uses powerful new methods of genomic analyses to develop closer, flanking markers for EOAD and to define the genomic limits for subtraction hybridization strategies.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Unknown (R35)
Project #
Application #
Study Section
Aging Review Committee (AGE)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Schools of Medicine
United States
Zip Code
Liu, S J; Crum, R M; Anthony, J C (2001) A latent variable approach to studying risk factors for Alzheimer's disease. Neuroepidemiology 20:31-9
Arrowsmith, J E; Grocott, H P; Reves, J G et al. (2000) Central nervous system complications of cardiac surgery. Br J Anaesth 84:378-93
Arrowsmith, J E; Grocott, H P; Newman, M F (1999) Neurologic risk assessment, monitoring and outcome in cardiac surgery. J Cardiothorac Vasc Anesth 13:736-43
Xu, P T; Gilbert, J R; Qiu, H L et al. (1998) Regionally specific neuronal expression of human APOE gene in transgenic mice. Neurosci Lett 246:65-8
Breitner, J C; Jarvik, G P; Plassman, B L et al. (1998) Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years. Alzheimer Dis Assoc Disord 12:40-4
Roses, A D (1998) Alzheimer diseases: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. Am J Med Genet 81:49-57
Steffens, D C; Plassman, B L; Helms, M J et al. (1997) A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. Biol Psychiatry 41:851-6
Roses, A D (1997) Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis 4:170-85
Tardiff, B E; Newman, M F; Saunders, A M et al. (1997) Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann Thorac Surg 64:715-20
Roses, A D (1997) Genetic testing for Alzheimer disease. Practical and ethical issues. Arch Neurol 54:1226-9

Showing the most recent 10 out of 73 publications